Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model

Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model

Abstract Pancreatic cancer (PC) has a very low survival rate mainly due to late diagnosis and refractoriness to therapies. The latter also cause adverse effects negatively affecting the patients’ quality of life, often requiring dose reduction or discontinuation of scheduled treatments, compromising...

Full description

Bibliographic Details
Main Authors: Concetta Panebianco, Federica Pisati, Annacandida Villani, Annapaola Andolfo, Marynka Ulaszewska, Edoardo Bellini, Carmelapia Ferro, Renato Lombardi, Fabrizio Orsenigo, Tiziana Pia Latiano, Beatrice Belmonte, Claudio Tripodo, Francesco Perri, Valerio Pazienza
Format: Article
Language:English
Published: Nature Publishing Group 2023-04-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-023-01397-y

Internet

https://doi.org/10.1038/s41420-023-01397-y

Similar Items